Serum 14-3-3η protein is associated with clinical and serologic features of Sjögren’s syndrome in patients with systemic lupus erythematosus: a cross-sectional analysis
| Autor: | Tamer A. Gheita, Amira M Elsonbaty, Mona H. Elzohri, A.M. Rashed, Dalia Tarik, Zeiad H Eldaly, Nevin Hammam, Nada M. Gamal |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
030203 arthritis & rheumatology
medicine.medical_specialty Systemic lupus erythematosus business.industry Cross-sectional study Arthritis General Medicine medicine.disease Gastroenterology Rheumatology Serology 03 medical and health sciences Titer 0302 clinical medicine immune system diseases Internal medicine Rheumatoid arthritis medicine In patient 030212 general & internal medicine skin and connective tissue diseases business |
| Zdroj: | Clinical Rheumatology. 39:2603-2610 |
| ISSN: | 1434-9949 0770-3198 |
| DOI: | 10.1007/s10067-020-05033-3 |
| Popis: | Systemic lupus erythematosus (SLE) and Sjogren’s syndrome (SS) may coexist and carry a higher risk for future comorbidities. Although 14-3-3η protein is recently a known diagnostic marker in rheumatoid arthritis (RA), its role has not been investigated in SLE. The aim of this study was to compare serum 14-3-3η protein level in SLE and RA patients and to examine its association with clinical and laboratory features in SLE patients. Eighty-four SLE patients and 39 RA patients were included. Sociodemographic, SLE disease activity index (SLEDAI), and damage index were assessed for SLE patients. Data about secondary SS were collected. 14-3-3η was measured by ELISA; titres above 0.19 ng/ml were considered positive. Serum 14-3-3η protein in SLE was significantly lower than in RA (0.37 ± 0.09 vs 1.5 ± 0.51; p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink